Cessatech Yönetim

Yönetim kriter kontrolleri 1/4

Cessatech CEO'su Jes Trygved, Jan2020 tarihinde atandı, in görev süresi 4.83 yıldır. şirketin hisselerinin 5.32% doğrudan sahiptir ve bu hisselerin değeri DKK 12.61M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.9 yıl ve 4.3 yıldır.

Anahtar bilgiler

Jes Trygved

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.8yrs
CEO sahipliği	5.3%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

Is Cessatech (NGM:CESSA) In A Good Position To Invest In Growth?

Aug 03

CEO

Jes Trygved (51 yo)

4.8yrs

Görev süresi

Mr. Jes Trygved serves as Chief Executive Officer at Cessatech A/S (formerly known as Cessatech ApS) since 2020. Mr. Trygved has experience within the biotech and pharmaceutical industry including time spe...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jes Trygved	Chief Executive Officer	4.8yrs	Veri yok	5.32% DKK 12.6m
Martin Juhl	Chief Scientific Officer and Head of CMC	less than a year	Veri yok	Veri yok
Louise Bak	Head of Regulatory Affairs	2.7yrs	Veri yok	Veri yok
Malene Cording	Head of Clinical Development & Operations	less than a year	Veri yok	Veri yok
Mai Gregersen	Head of Quality Assurance	less than a year	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: CESSA 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Flemming Jensen	Independent Director	4.3yrs	Veri yok	Veri yok
Martin Olin	Independent Chairman of the Board	4.3yrs	Veri yok	2.05% DKK 4.9m
Charlotte Videbaek	Independent Director	4.3yrs	Veri yok	1% DKK 2.4m
Rachel Gravesen	Director	2.8yrs	Veri yok	1.17% DKK 2.8m
Anders Dombernowsky-Toft	Director	less than a year	Veri yok	0.29% DKK 691.7k

4.3yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CESSA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Cessatech Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Cessatech A/S Announces Board Changes

Cessatech A/S, Annual General Meeting, Mar 27, 2024

Cessatech A/S, Annual General Meeting, Mar 17, 2023

High number of new and inexperienced directors

Cessatech A/S, Annual General Meeting, Mar 26, 2021

Recent updates

Cessatech A/S to Report Q3, 2024 Results on Nov 13, 2024

Is Cessatech (NGM:CESSA) In A Good Position To Invest In Growth?

Cessatech A/S to Report Q2, 2024 Results on Aug 21, 2024

Cessatech A/S Announces Board Changes

Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001

Cessatech A/S to Report Q1, 2024 Results on May 15, 2024

New major risk - Negative shareholders equity

Cessatech A/S, Annual General Meeting, Mar 27, 2024

New minor risk - Shareholder dilution

Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children

Cessatech A/S to Report Q3, 2023 Results on Nov 16, 2023

Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001

Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation

Cessatech A/S to Report Q2, 2023 Results on Aug 24, 2023

Cessatech A/S, Annual General Meeting, Mar 17, 2023

Cessatech A/S to Report Fiscal Year 2022 Results on Mar 03, 2023

High number of new and inexperienced directors

Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval

Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate

Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001

Cessatech A/S Expects to Report on its Bioavailability Trial 0204 Within Few Weeks

Cessatech Reports First Patient Dosed in Pharmacokinetic Trial in Children of Lead Product Candidate

Cessatech Reports Last Subject Dosed in Bioavailability Trial of Lead Product Candidate

Cessatech A/S, Annual General Meeting, Mar 26, 2021

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş